Physiologically‐Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID‐19 in Geriatrics
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2600
Abstract: Janus kinase (JAK) inhibitors baricitinib and tofacitinib are recommended by the US National Institutes of Health as immunomodulatory drugs for coronavirus disease 2019 (COVID‐19) treatment. In addition, baricitinib has recently received Emergency Use Authorization from… read more here.
Keywords: baricitinib; based pharmacokinetic; renal impairment; baricitinib tofacitinib ... See more keywords
FRI0124 EFFICACY AND SAFETY OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS: DATA FROM REAL-WORLD
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.6321
Abstract: Oral targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) including baricitinib and tofacitinib (JAKi), are the latest addition to the therapeutic options for rheumatoid arthritis (RA).To assess and compare the efficacy and safety of Baricitinib and… read more here.
Keywords: baricitinib; baricitinib tofacitinib; efficacy safety;